- Home
- ELVA vs SLS Comparison
ELVA vs SLS Comparison
Compare ELVA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- SLS
- Stock Information
- Founded
- ELVA 1996
- SLS 2012
- Country
- ELVA Canada
- SLS United States
- Employees
- ELVA N/A
- SLS N/A
- Industry
- ELVA
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- ELVA
- SLS Health Care
- Exchange
- ELVA Nasdaq
- SLS Nasdaq
- Market Cap
- ELVA 71.0M
- SLS 75.3M
- IPO Year
- ELVA N/A
- SLS N/A
- Fundamental
- Price
- ELVA $2.31
- SLS $1.32
- Analyst Decision
- ELVA Strong Buy
- SLS Buy
- Analyst Count
- ELVA 4
- SLS 1
- Target Price
- ELVA $8.75
- SLS $3.00
- AVG Volume (30 Days)
- ELVA 32.7K
- SLS 753.9K
- Earning Date
- ELVA 12-31-2024
- SLS 11-13-2024
- Dividend Yield
- ELVA N/A
- SLS N/A
- EPS Growth
- ELVA N/A
- SLS N/A
- EPS
- ELVA 0.02
- SLS N/A
- Revenue
- ELVA $49,490,000.00
- SLS N/A
- Revenue This Year
- ELVA $4.36
- SLS N/A
- Revenue Next Year
- ELVA $80.25
- SLS N/A
- P/E Ratio
- ELVA $133.94
- SLS N/A
- Revenue Growth
- ELVA 45.33
- SLS N/A
- 52 Week Low
- ELVA $1.67
- SLS $0.50
- 52 Week High
- ELVA $4.58
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- ELVA 57.26
- SLS 60.02
- Support Level
- ELVA $2.06
- SLS $1.22
- Resistance Level
- ELVA $2.74
- SLS $1.39
- Average True Range (ATR)
- ELVA 0.21
- SLS 0.08
- MACD
- ELVA 0.02
- SLS 0.02
- Stochastic Oscillator
- ELVA 57.43
- SLS 72.00
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and industry leading battery longevity. Geographically it earns key revenue from the United States.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.